2 min read

Highlights From Scope 2021, and the Clinical Trial Road Ahead

Mar 17, 2021 12:44:02 PM

Those in the clinical trial industry understand that there are several barometers that can be used to gauge the overall state of the industry. Chief among these are the “big conferences” that occur each year, such as  SCOPE, J.P. Morgan week, and D.I.A.  

With another SCOPE behind us, we thought we’d take the time to summarize what we felt were some of the important industry trends and topics discussed in detail this year. 

 

An Increased Focus on Sensors in Trials

With the outside world still continuing to keep the majority of patients at home, a large focus at this year’s scope was on the promise and potential of sensors and wearables in the market. 

New ideas about the best ways to capture and use clinical trial data were bolstered by arguments showing the positive impact to drug development that comes from combining trial data with supplementary patient data. While the overall sentiment was positive and hopeful around the growing use of sensors, many cautioned that there would need to be a large concerted effort to centralize their deployment and standards of use with review boards and regulators worldwide. 

Presentation(s) of Note: 

Sensors and Wearables in a Decentralized World - Play back available now.
Ali Holland,Exec GM, Digital and Decentralized Solutions

Meeting all Endpoint Needs with a Single Platform
Geoff Gill, President, Shimmer Americas, Shimmer Research

 

The Growing World of Decentralized and Remote Trials

Continuing the sentiments of 2020, decentralization and remote trials continued to influence the conference at large. Many industry organizations touted their plans and capabilities when it came to administering trials at home, in-office, or anywhere in between. 

Furthermore, more companies were speaking to the general needs and circumstances that have led us towards decentralization. This includes not only COVID-19, but older research indicating how many patients, sites, and even sponsors are burdened and constrained by in-clinic only trials. 

Presentation(s) of Note: 

Scaling Decentralized Trials: Best Practices and Lessons Learned to Help Strengthen Patient-Centricity & Trial Delivery
Nagaraja (Sri) Srivatsan, Senior Vice President and Chief Digital Officer, Technology Solutions, IQVIA
Christopher Varner, Associate Director, Virtual Trials, IQVIA

 

The Effect of COVID-19 on Our Industry

For those who didn’t see this one coming, it only took a brief glance at this year’s agenda to know what would be a major talking point at this year’s SCOPE.

COVID-19 drove discussions pertaining to topics relevant across our entire industry. This included COVID as a driver for innovation, but also flexibility, speed, new ways of running trials, changing regulations, and the lasting legacy of clinical trials. 

Presentations of note:

Keynote Presentation: COVID-19: How an External Event Redoubled Janssen’s Culture of Innovation
Darren Weston, Vice President, Integrated Data Analytics & Reporting (IDAR), Janssen

 

Overall

As one could expect, several of the main themes of this year’s SCOPE were a direct result of our world in 2020. What SCOPE cemented, however, was that the “new norm” of doing things, one brought upon by COVID, is definitely here to stay.

Dan Horsey

Written by Dan Horsey

Dan joins the Marketing team at Medable. Previously, Dan was a Content Manager at Signant Health and a Marketing Manager at IQVIA. He got his start in healthcare marketing in 2014, working with Pharmacy Benefits Managers in the managed Medicare and Medicaid spaces, and has been writing in healthcare capacities for over 10 years. Dan has extensive experience in creating both long and short forms of content across a wide variety of mediums. He earned his Bachelor of Arts in Communications from West Chester University in 2009. In his spare time, Dan composes music as a hobby and plays guitar for a Philadelphia based hardcore band.

Featured